DKMS Stiftung Leben Spenden   Report issue

For profit Phase 2
Founded: Tubingen Germany (1991)

Organization Overview

First Clinical Trial
2019
NCT04232241
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

DKMS Stiftung Leben Spenden

Active Ingredients

Drugs in Phase 2 Trials (1)

allogeneic stem cells (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Leukemia (Phase 2)

Leukemia, Lymphoid (Phase 2)

Leukemia, Myeloid, Acute (Phase 2)

Myelodysplastic Syndromes (Phase 2)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 2)

Preleukemia (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1